Reaction
Craniofacial Fracture reporting signals
As of the last recalculation, Craniofacial Fracture appears in 798 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES (PRR 33.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 11 | 33.8 | 33.8 |
| Eptinezumab-Jjmr | 6 | 17.3 | 17.3 |
| Vibegron | 5 | 16.4 | 16.4 |
| Asfotase Alfa | 6 | 15.7 | 15.7 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate | 5 | 14.6 | 14.6 |
| Esketamine Hydrochloride | 9 | 13.3 | 13.3 |
| Brivaracetam | 4 | 11.7 | 11.7 |
| Emicizumab | 5 | 10.6 | 10.6 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 4 | 10.4 | 10.4 |
| Risankizumab-Rzaa | 31 | 10.2 | 10.3 |
| Emtricitabine And Tenofovir Alafenamide | 4 | 9.2 | 9.2 |
| Rimegepant Sulfate | 4 | 8.3 | 8.3 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 5 | 7.2 | 7.2 |
| Abaloparatide | 6 | 5.4 | 5.4 |
| Pimavanserin Tartrate | 8 | 3.8 | 3.8 |
| Guselkumab | 5 | 3.7 | 3.7 |
| Galcanezumab-Gnlm | 4 | 3.3 | 3.3 |